A new mouse model of anaerobic infection with Bacteroides fragilis alone or in a mixed infection with Escherichia coli is described. It is established by implantation under the skin of a filter paper disk saturated with the appropriate bacterial suspension. The penetration of antibiotics into the implantation site can be detected by assaying the disk. The local infection can be both standardized and evaluated by determining the bacterial count on the disk. The antimicrobial efficacy of ceftizoxime was compared with other commercially available antibiotics administered in a single dose, 40 mg/kg subcutaneously, one hour after implantation of the disk. Using such a regimen ceftizoxime was found to be superior to a clindamycingentamicin combination and equal to or superior to cefoxitin in these models.
A new mouse model of anaerobic infection with Bacteroides fragilis alone or in a mixed infection with Escherichia coli is described. It is established by implantation under the skin of a filter paper disk saturated with the appropriate bacterial suspension. The penetration of antibiotics into the implantation site can be detected by assaying the disk. The local infection can be both standardized and evaluated by determining the bacterial count on the disk. The antimicrobial efficacy of ceftizoxime was compared with other commercially available antibiotics administered in a single dose, 40 mg/kg subcutaneously, one hour after implantation of the disk. Using such a regimen ceftizoxime was found to be superior to a clindamycingentamicin combination and equal to or superior to cefoxitin in these models.
The possibility of developing models of infection in mice with Bacteroides fragilis, both alone and in combination with Escherichia coli was explored.
Anew method has recently been used in our laboratories to produce local infections with aerobic bacteria in mice1). These infections are easily evaluated and respond to appropriate antibiotic therapy. This methodology was adapted to produce the anaerobic models described in this study. Ceftizoxime is a broad spectrum cephalosporin with activity against many strains of B. fragilis2). The therapeutic activity of this cephalosporin was compared with cefoxitin and a clindamycin-gentamicin combination in these experimental infections. They were sacrificed on day 7, the areas surrounding the disks were observed and the disks were removed, suspended and diluted in Schaedler's broth and the dilutions counted to determine the number of bacteria, colony forming units (cfu) per disk. The counts were done on Schaedler's agar in an anaerobic chamber for B. fragilis and on Trypticase soy agar, aerobically for E. coll. The plates were incubated at 37°C. Groups of 10 mice were used for each antibiotic tested and for non-treated infected controls.
Drugs
Cyclophosphamide was a commercial preparation from Mead Johnson.
Cefoxitin was an investigational sample from Merck, Rahway, N. J. Clindamycin and gentamicin were commercial preparations. Ceftizoxime was a research sample from Fujisawa, Osaka, Japan. All of the antimicrobial agents except gentamicin were administered at 40 mg/kg, sc. Gentamicin was used at 1.0 mg/kg, sc. The compounds were given as a single dose, one hour post implantation.
Detection of Antibiotics in the Implanted Disk Groups of 15 mice per antibiotic were injected subcutaneously immediately after implantation of a 1.0% carrageenan-saturated disk. The mice were sacrificed one hour after administration of the antibiotics. The disks were removed and five from each group were placed on agar plates seeded with Staphylococcus aureus 209P, E. coli KN, and B. fragilis ATCC 25285. The plates were incubated overnight at 37°C and zones of inhibition were recorded.
Results
Pretreatment of mice with cyclophosphamide allowed establishment of a consistent infection with B. fragilis impregnated into a disk and implanted under the skin. There were no deaths in these mice at day 7. A consistent infection with B. fragilis could also be established if a mixed inoculum consisting of E. coli and B. fragilis was used in the normal mouse. Early death occurred in this infection probably due to the E. coll. When E. coli was eliminated by treatment, there was no death even though B. fragilis sometimes persisted. A smaller E. coli inoculutn was required to produce death in the mixed infection in neutropenic mice (Table 1) . In all of the infections, the disks in the surviving control-untreated mice were covered with purulent exudate and contained viable B. fragilis.
The in vitro activities of each of the antibiotics against the B. fragilis and E. coli strains used in these infections are given in Table 2 . At low inoculum levels, B. fragilis was sensitive to each of the antibiotics except gentamicin. There was a marked decrease in the activity of ceftizoxime at the higher inoculum used. E. coli was sensitive to each of the antibiotics except clindamycin.
The therapeutic efficacies of a single dose of ceftizoxime and comparative compounds in these infections are given in Table 3 . In the mixed infections, ceftizoxime protected against death and ceftizoxime. In general, the site surrounding the disk implant looked more purulent and necrotic in most of these mice than in the untreated control infections. In the B. fragilis infection in the neutropenic mice, the median count per disk for the clindamycin-gentamicin group was the same as in the ceftizoxime group. Although one out of 9 disks was negative for B. fragilis, the site surrounding the disk implant in the remaining mice had more purulent exudate than those in the control, untreated infections.
Cefoxitin protected against death and cleared or reduced the counts of both E. coli and B. fragilis in the normal mouse. However, it was less effective than ceftizoxime in the neutropenic mouse both in preventing death and in decreasing the counts of bacteria per disk. The disks were heavily covered with exudate. In the B. fragilis infection in the neutropenic mouse, the site of the disk was covered with purulent exudate in all of the animals. There was less of a reduction in the median count per (Table 4) .
Ceftizoxime, clindamycin, gentamicin and cefoxitin disk levels were sufficient to be detected by activity on plates seeded with E. coli and Staphylococcus aureus. However, only ceftizoxime and clindamycin levels were sufficient to be detected by activity against the B. fragilis strain used. 
Discussion
Several animal models of anaerobic infection have been previously described and reviewed in the literature. Establishment of Bs fragilis infection usually requires the use of mucin or agar or synergy with other microorganisms3-8). In order to predict antimicrobial efficacy against B. fragilis, in vivo, the most commonly used model of intra-abdominal sepsis is produced in Wistar rats challenged ip with pooled colonic contents in gelatin capsules9,10,11). The resulting infection is biphasic, initially there is acute peritonitis, E. coil bacteremia and mortality. The survivors then develop intra-abdominal abscesses in which anaerobes predominate. Challenge ip with E. coli alone in gelatin capsules produces bacteremia while challenge ip with B. fragilis alone in gelatin capsules produces abscesses.
A model of local infection with B. fragilis alone and in combination with E. coli was developed to test for in vivo efficacy of antimicrobial agents against B. fragilis. The mouse models of anaerobic infection described here can be easily standardized to give reproducible infections. Establishment of the infection by use of an implanted filter paper disk also allows detection of the penetration of antibiotics to the site of infection and ease in estimating the number of bacteria at the local site. These infections allow assessment of therapeutic activity of antimicrobial agents against B. fragilis alone as well as in a model of polymicrobic infection which is more analogous to the naturally acquired infections in man and to the course of infection in the rat model commonly used to predict efficacy against anaerobes11). In these mouse infections, death also occurs early due to E. coli while Bs fragilis alone does not result in fatal infection.
In these mouse models, infection with B. fragilis could only be established consistently if the mice were made neutropenic or if a mixed infection was established with E. coli, either in normal or in neutropenic mice. These findings are consistent with the observations of previous investigators who required mucin or agar to establish B. fragilis and those who have demonstrated the need for bacterial synergy with other microorganisms in order to produce B. fragilis infections.
The efficacy obtained with ceftizoxime and comparative compounds in this mouse model is in agreement with the results obtained by others in the commonly accepted Wistar rat model12).
